Lamivudine for chronic hepatitis B: a brief review
Braz. j. infect. dis
;
12(5): 355-357, Oct. 2008.
Article
in English
| LILACS
| ID: lil-505345
ABSTRACT
Until recently, the only generally approved treatment for chronic hepatitis B was alpha-interferon; however, it gives only moderate efficacy in terms of sustained response (biochemical, virological and histological). In fact, only 20 percent to 40 percent of treated patients respond to therapy, with lower percentages (~ 10 percent) among patients infected with precore-mutant strains of HBV (HBeAb HBV-DNA positive). The FDA of the USA approved the use of lamivudine in adult patients affected by chronic hepatitis B in 1998. In this review, we focused on the pharmacokinetic and pharmacodynamic properties and efficacy and tolerability of lamivudine in the treatment of chronic hepatitis B cases that are both HBeAg and anti-HBe-positive.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Antiviral Agents
/
Lamivudine
/
Hepatitis B, Chronic
Limits:
Humans
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2008
Type:
Article
Affiliation country:
Italy
Institution/Affiliation country:
Sondrio Hospital/IT
Similar
MEDLINE
...
LILACS
LIS